Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer (NCT06234748)
Pilot Phase II Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer
🩺 Plain-English Summary (8th-Grade Level)
This study seeks to study the population of HPV-related oropharynx cancer patients that appear to be at highest risk for treatment failure with loco-regional failure and distant metastases including cT4 or cN3. The study team aims to determine if it is feasible to use multi-modality imaging (both DCE MRI and FDG-PET) to optimize the radiation boost in high risk p16+ OPSCC with similar or decreased toxicity compared to historic standard therapy.
Who can join: Review the eligibility criteria below.
Location: University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Oropharynx Cancer
- Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer) — La Jolla, California
- Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx — Durham, North Carolina
- Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly — Jacksonville, Florida
- Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer — Philadelphia, Pennsylvania
- Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer — Pittsburgh, Pennsylvania
Explore by condition: All Oropharynx Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.